• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Riptide Bioscience, National Cancer Institute partner

Riptide Bioscience, National Cancer Institute partner

October 6, 2016
CenterWatch Staff

Henry Lopez, executive vice president of Riptide Bioscience, has announced the execution of a Cooperative Research and Development Agreement (NCI CRADA #03045) with the National Cancer Institute (NCI), part of the NIH.  The agreement carries a three-year term and is entitled, Evaluation of Riptide Bioscience's Proprietary Peptide RP-182 in Preclinical Studies for the Treatment of Pancreatic Cancer.  Research under the CRADA is intended to generate data to support an Investigational New Drug filing of this agent with the FDA.

Pancreatic cancer is among the most lethal of all diseases; 90% of patients die within one year of diagnosis.  Even following surgical removal of the primary tumor, long-term survival rates are poor, with tumors recurring in virtually all patients. 

Lopez stated, "We're delighted to finalize this agreement with NCI and believe it is an important affirmation of the strength of Riptide's research program.  Our development team has already been working closely with NCI for several years, and NCI scientists have had an opportunity to test RP-182 in transgenic models of pancreatic tumors, with significant success.  RP-182strongly complements the effectiveness of chemotherapies such as gemcitabine, substantially arresting tumor growth and extending survival."

Lopez continued, "We believe that RP-182 will prove to be complementary to both conventional chemotherapies and emerging immunotherapies.  RP-182 alters the balance of cell populations in the tumor microenvironment so as to become tumor-inhibiting rather than tumor-promoting.  We think this approach has real potential to become the 'third leg' of a therapeutic tripod that currently includes chemotherapy and immunotherapy."

The National Cancer Institute's team on the RP-182 project comes from the Thoracic and Gastrointestinal Oncology Branch, in the Center for Cancer Research, Bethesda, Maryland.  The NCI team is headed by Dr. Udo Rudloff (MD, PhD), a physician scientist with both research and patient-care responsibilities.

Dr. Rudloff stated, "The anti-cancer efficacy of RP-182 in combination with chemotherapy compares favorably to previous treatment modalities which were tested in similar transgenic animal models of pancreatic cancer, and which are currently either in clinical trials or have received regulatory approval for the treatment of pancreatic cancer.  Our expectation and hope is to make such promising therapeutics available to patients afflicted by pancreatic cancer."

Riptide Bioscience, with laboratories in Vallejo, California, maintains an intensive program of research into peptide-based therapeutics. 

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing